Table 3.
Characteristics of the study population 2 (maintenance IFN therapy, n=14)
| Group 2-A with intake of Aminofeel | Group 2-B without intake of Aminofeel | P value | ||||
|---|---|---|---|---|---|---|
| No. subjects |
n |
11 |
|
3 |
|
|
| Sex |
male/female |
3/8 |
|
3/0 |
|
0.02 |
| Age |
(mean ± SD), years |
65.2 ± 5.9 |
|
64.3 ± 6.0 |
|
NS |
| Age range |
years |
56 - 73 |
|
58 - 70 |
|
|
| IFN therapy for the first time/retreatment |
n |
5/6 |
|
0/3 |
|
NS |
| Liver diseases |
CH-C |
1 |
9.1% |
0 |
0.0% |
|
| |
CH-C & AIH |
1 |
9.1% |
0 |
0.0% |
|
| |
CH-C & post HCV-related HCC |
1 |
9.1% |
1 |
33.3% |
|
| |
LC-C |
5 |
45.5% |
0 |
0.0% |
|
| |
LC-C & LC-B |
1 |
9.1% |
0 |
0.0% |
|
| |
LC-C & post HCV-related HCC |
2 |
18.2% |
2 |
66.7% |
|
| Liver diseases |
Only CH |
2 |
18.2% |
0 |
0.0% |
NS |
| |
LC or post HCC treatmnet |
9 |
81.8% |
3 |
100.0% |
NS |
| HCV genotype |
1b |
8 |
72.7% |
2 |
66.7% |
NS |
| |
2a |
2 |
18.2% |
0 |
0.0% |
NS |
| |
unknown |
1 |
9.1% |
1 |
33.3% |
NS |
| HCV RNA level |
High |
11 |
100.0% |
3 |
100.0% |
NS |
| |
Low |
0 |
0.0% |
0 |
0.0% |
NS |
| Extrahepatic manifestations |
Diabetes millitus (positive %) |
5 |
45.5% |
1 |
33.3% |
NS |
| |
Hypertensiton (positive %) |
6 |
54.5% |
1 |
33.3% |
NS |
| |
Hyperlipidemia (positive %) |
0 |
0.0% |
0 |
0.0% |
NS |
| |
Oral lichen planus (positive %) |
1 |
9.1% |
0 |
0.0% |
NS |
| |
Hyperthyroidism (positive %) |
2 |
18.2% |
0 |
0.0% |
NS |
| |
Hypothyroidism (positive %) |
1 |
9.1% |
0 |
0.0% |
NS |
| Total of Aminofeel intake (g) |
mean ± SD |
2443.6 ± 3209.3 |
|
0 |
|
<0.01 |
| BMI |
mean ± SD |
24.3 ± 2.0 |
|
24.5 ± 3.1 |
|
NS |
| Obesity (BMI ≥ 25 kg/m2) |
n (%) |
4 |
36.4% |
1 |
33.3% |
NS |
| RBC (×104/μL) |
mean ± SD |
402.3 ± 62.3 |
|
417.3 ± 29.5 |
|
NS |
| Hb (g/dL) |
mean ± SD |
13.0 ± 1.5 |
|
13.1 ± 1.2 |
|
NS |
| PLT (×104/μL) |
mean ± SD |
9.4 ± 4.8 |
|
10.2 ± 4.9 |
|
NS |
| WBC (μL) |
mean ± SD |
3809.1 ± 1045.4 |
|
3500.0 ± 1558.8 |
|
NS |
| PT (%) |
mean ± SD |
80.7 ± 22.6 |
|
85.3 ± 10.5 |
|
NS |
| AST (U/I) |
mean ± SD |
83.9 ± 44.4 |
|
73.7 ± 8.4 |
|
NS |
| ALT (U/I) |
mean ± SD |
77.9 ± 34.9 |
|
68.3 ± 6.5 |
|
NS |
| LDH (U/I) |
mean ± SD |
238.7 ± 79.1 |
|
211.0 ± 31.2 |
|
NS |
| gamma GTP (U/I) |
mean ± SD |
57.7 ± 35.0 |
|
63.0 ± 23.4 |
|
NS |
| ChE (U/I) |
mean ± SD |
166.3 ± 98.4 |
|
188.0 ± 42.3 |
|
NS |
| TP (g/dL) |
mean ± SD |
7.4 ± 0.6 |
|
7.7 ± 0.6 |
|
NS |
| Alb (g/dL) |
mean ± SD |
3.59 ± 0.5 |
|
3.67 ± 0.1 |
|
NS |
| T.Bil (mg/dL) |
mean ± SD |
1.0 ± 0.3 |
|
1.1 ± 0.4 |
|
NS |
| FBS (mg/dL) |
mean ± SD |
112.7 ± 18.4 |
|
93.3 ± 24.0 |
|
NS |
| HbA1c (%) |
mean ± SD |
5.6 ± 0.8 |
|
5.4 ± 0.9 |
|
NS |
| TC (mg/dL) |
mean ± SD |
166.7 ± 20.8 |
|
134.5 ± 9.2 |
|
NS |
| AFP (ng/dL) |
mean ± SD |
33.7 ± 70.2 |
|
11.7 ± 3.8 |
|
NS |
| IRI (μU/mL) |
mean ± SD |
20.8 ± 15.1 |
|
15.6 ± 8.8 |
|
NS |
| HOMA-beta |
|
185.7 ± 184.0 |
|
208.6 ± 69.7 |
|
NS |
| HOMA-IR |
|
6.0 ± 5.3 |
|
3.9 ± 3.2 |
|
NS |
| Zn (μg/dL) |
mean ± SD |
62.8 ±10.7 |
|
67.0 ± 2.8 |
|
NS |
| Course of IFN therapy |
Peg-IFN alpha 2a monotherapy |
4 |
36.4% |
2 |
66.7% |
|
| |
Peg-IFN alpha 2a/RBV - (change) - Peg-IFN alpha 2a monotherapy |
4 |
36.4% |
1 |
33.3% |
|
| |
IFN beta - (change) - Peg-IFN alpha 2b/RBV - (change) - Peg-IFN alpha 2a monotherapy |
1 |
9.1% |
0 |
0.0% |
|
| |
Peg-IFN alpha 2a monotherapy - (change) - Peg-IFN alpha 2a/RBV - (change) - Peg-IFN alpha 2a monotherapy |
1 |
9.1% |
0 |
0.0% |
|
| |
Peg-IFN alpha 2a monotherapy - (change) - Peg-IFN alpha 2b/RBV |
1 |
9.1% |
0 |
0.0% |
|
| Effect of IFN therapy |
SVR |
2 |
18.2% |
0 |
0.0% |
NS |
| Non-SVR | 9 | 81.8% | 3 | 100.0% | NS |
HCV, hepatitis C virus; CH-C, chronic hepatitis C; LC-C, liver cirrhosis type C; LC-B, chronic hepatitis type B; HCC, hepatocellular carcinoma; AIH, autoimmune hepatitis; IFN, interferon; RBC, red blood cell; Hb, hemoglobin; PLT, platelets; WBC, white blood cell; PT, prothrombin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; gamma GTP, gamma-glutamyltransferase; ChE, cholinesterase; TP, total protein; Alb, albumin; T.Bil, total bilirubin; FBS, fasting blood glucose; TC, total; cholesterol; IRI, immunoreactive insulin; Zn, zinc; SVR, sustained virological response; NS, not significant; IFN, interferon; RBV, ribavirin.